Last reviewed · How we verify
Yunhe Pharmaceutical (Tianjin) Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| INR101 | INR101 | phase 3 | Vitamin K antagonist | VKORC1 | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Joon Bum Kim · 1 shared drug class
- Population Health Research Institute · 1 shared drug class
- US Department of Veterans Affairs · 1 shared drug class
- University Hospital, Bonn · 1 shared drug class
- University Hospital, Limoges · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Yunhe Pharmaceutical (Tianjin) Co., Ltd:
- Yunhe Pharmaceutical (Tianjin) Co., Ltd pipeline updates — RSS
- Yunhe Pharmaceutical (Tianjin) Co., Ltd pipeline updates — Atom
- Yunhe Pharmaceutical (Tianjin) Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Yunhe Pharmaceutical (Tianjin) Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yunhe-pharmaceutical-tianjin-co-ltd. Accessed 2026-05-17.